Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma : Episode 9
Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
Experts on multiple myeloma discuss prophylactic supportive measures to prevent CRS and ICANS in patients who receive GPRC5D therapy.
EP: 1.Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
EP: 2.Adverse Event Management with BCMA Therapy
EP: 3.GPRC5D Therapy: Unique Challenges in Adverse Event Management
EP: 4.Overview of Long-term Follow-up from MonumenTAL-1
EP: 5.Overview of Other GPRC5D Therapy Clinical Trials
EP: 6.Administration and Dosing Management
EP: 7.Clinical Perspective on AE Tolerance
EP: 8.Clinical Experience in Managing AEs in GPRC5D Therapy
Now Viewing
EP: 9.Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
EP: 10.Insights on REMS Programs and Strategies for Effective Patient Care
EP: 11.Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
EP: 12.Adverse Event Management Strategies in GPRC5D Therapy
EP: 13.Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Recent Videos
Related Content
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
FNU Fatima, MBBS;Faryal Arif, MBBS;Muhammad Hamza Gul, MBBS, MD;Neha Siddiqui, MBBS;Muhammad Zulqarnain, MBBS;Abdul Baseer Wardak, MBBS
November 8th 2024Article
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
